HIV Primary Care

What’s New in HIV Primary Care

Release Date: September 30, 2021
Expiration Date: September 30, 2022
Estimated time to complete: 3 hours

FACULTY

Melanie Thompson, MD
Principal Investigator
AIDS Research Consortium of Atlanta

Tulika Singh, MD, MS, AAHIVS, FACP
Director of Research & Associate Chief Medical Officer
DAP Health

Mamta K. Jain, MD, MPH
Professor of Internal Medicine
Division of Infectious Disease
UT Southwestern Medical Center

Waridibo Allison, MD, PhD
Assistant Professor of Infectious Disease
UT Health San Antonio
Medical Director – San Antonio AIDS Foundation

William R. Short, MD, MPH, FIDSA
Associate Professor of Medicine and Obstetrics and Gynecology
Perelman School of Medicine at University of Pennsylvania

Jonathan Colasanti, MD, MSPH
Medical Director Grady Infectious Disease Program
Emory University / Grady Health System

Allison Agwu, MD, ScM
Associate Professor of Pediatric and Adult Infectious Diseases
Johns Hopkins University School of Medicine

Michael A. Horberg, MD, MAS
Associate Medical Director
Kaiser Permanente Mid-Atlantic Permanente Medical Group


TARGET AUDIENCE

This activity is intended for frontline providers of care to persons at risk for or who are living with HIV, including specialist and primary care Physicians, NPs, PAs, Nurses, and Pharmacists. Other HIV care team members are also encouraged to participate.


LEARNING OBJECTIVES/LEARNING OUTCOMES

As a result of participating in this activity, learners should be better able to:

  • Work with your team to develop strategies for initial and immediate follow up care engagement and vaccines
  • Manage comorbidities and non-AIDS complications in your clients with HIV
  • Address issues specific to cisgender women and transgender men of childbearing potential, adolescents, and transgender populations

CREDITS

American Academy of CME is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
 
 

Physicians
American Academy of CME, Inc. designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NPs and Nurses
American Academy of CME, Inc. designates this educational activity for 3.0 contact hours (1.1 pharmacotherapeutic contact hours).

PAs
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credits. Approval is valid until September 30, 2022. PAs should only claim credit commensurate with the extent of their participation.

All other members of the HIV Care team will receive a certificate of participation.

Resources to Support You and Your Care Team:
Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2020 Nov 6:ciaa1391. doi: 10.1093/cid/ciaa1391. Epub ahead of print. PMID: 33225349.  Available at: http://www.idsociety.org/practice-guideline/primary-care-management-of-people-with-hiv/


HOW TO RECEIVE CREDIT

There is no fee to participate in this activity. To obtain your certificate of credit/participation, you must read the CME/CE information, review the activity modules, and complete the activity assessment and evaluation. Upon submission, your CE certificate will be emailed to you within 24 hours.

NOTE: There is only one (1) evaluation for the entire activity.  Please wait until you have viewed all the modules of interest before completing the evaluation.


DISCLOSURES

This accredited continuing education activity, which originally appeared as part of ACTHIV 2021, is provided by American Academy of CME, Inc.

The 15th Annual American Conference for the Treatment of HIV (ACTHIV 2021) was held virtually May 20-22, 2021. The conference was supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co., Theratechnologies, and ViiV Healthcare.

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy, or ACTHIV. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Disclosure

This activity contains off-label discussion.

Faculty Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Tulika Singh, MD, MS; Waridibo Allison, MD, PhD; Jonathan Colasanti, MD, MSPH; Michael A. Horberg, MD, MAS

The following individuals have relevant financial relationships with ineligible companies to disclose:
Melanie Thompson, MD: Grant Recipient/Research Support – Cepheid, Cytodyn, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck Sharp Dohme, ViiV Healthcare;
Mamta Jain, MD, MPH: Advisory Board – Gilead Sciences, Grant Recipient/Research Support – Gilead Sciences, Regeneron, Janssen, GSK/ViiV, Merck;
William Short, MD, MPH, FIDSA: Advisory Board – ViiV Healthcare, Consultant – ViiV Healthcare;
Allison Agwu, MD, ScM: Advisory Board – Gilead Sciences, Merck, Consultant – Merck, Grant Recipient / Research Support – Gilead Sciences, Merck

Planner Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Beatrice Aladin; John Brooks, MD; Jose Castillo-Mancilla, MD; Sherrillyn Crooks, PA-C; Carlos del Rio, MD; Courtney V Fletcher, PharmD; Donna Futterman, MD; Rajesh Gandhi, MD; Mary Glenshaw, PhD, MPH, OTR/L; John JD Juchniewicz, MCIS, CHCP, FACEHP; H. Nina Kim, MD, MSc;  Natalie Kirkwood, RN, BSN, JD; Harry Lampiris, MD; Sharon Lee, MD; Vincent Lo Re, MD, MSCE; Amber McCracken; Lorenzo McFarland, DHA, MPH, MSW, PMP; Paul Miniter, MS; Edward Moylan, RP; Asa Radix, MD, PhD, MPH; Dianne Rausch PhD; Renslow Sherer, MD; Cheryl Smith, MD; Susan Weiss, FNP-BC, MSN, AAHIVS

The following individuals have relevant financial relationships to disclose:
Jillian Baron, MD, MPH: Employee (Spouse/Partner) – IQVIA;
Roger Bedimo, MD, MS: Advisory Board – ViiV Healthcare, Merck, Theratechnologies;
Michelle Cespedes, MD, MS: Advisory Board – Gilead Sciences, ViiV Healthcare, Grant Recipient/Research Support – Merck;
Eric Daar, MD: Consultant, Gilead Sciences, Merck, Genentech, Grant Recipient/Research Support – Gilead Sciences, ViiV Healthcare, Merck;
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board – ViiV Healthcare, Consultant – Gilead Sciences, ViiV Healthcare, Grant Recipient/Research Support – ViiV Healthcare, Speakers Bureau – Gilead Sciences, ViiV Healthcare;
Igho Ofotokun, MD, MSc: Advisory Board – ViiV Healthcare, Accordant Health Services, Takeda;
Tonia Poteat PhD, MPH, PA-C: Grant Recipient/Research Support: Gilead Sciences, ViiV Healthcare;
Jennifer Price, MD, PhD: Consultant – Theratechnologies, Shareholder (Spouse/partner) – AbbVie, Bristol Myers Squibb, Johnson & Johnson, Merck, Grant Recipient/Research Support – Gilead Sciences, Merck;
Jason Schafer, PharmD, MPH: Advisory Board – Merck, ViiV Healthcare; Grant Recipient/Research Support – Gilead Sciences, Merck;
William Short, MD, MPH, FIDSA: Advisory Board – ViiV Healthcare, Consultant – ViiV Healthcare;
Babaafemi Taiwo, MBBS: Advisory Board – Gilead Sciences, Merck, ViiV Healthcare, Consultant – Gilead Sciences, Merck, ViiV Healthcare;
Pablo Tebas, MD: Consultant: Merck, ViiV Healthcare;
Melanie Thompson, MD: Grant Recipient/Research Support – Cepheid Inc, Cytodyn Inc, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck Sharp Dohme, ViiV Healthcare;
Andrea Weddle, MSW: Advisory Board: Merck


Privacy Policy

For more information about the Academy’s privacy policy, please access http://www.academycme.org/privacy.htm

For questions related to CME/CE credit, contact CEservices@academycme.org


Hardware/Software Requirements

To access this activity hardware and software requirements are noted below.

This program should be viewed at a resolution of 1024 x 768 or higher using current versions of Microsoft Internet Explorer, Firefox, Chrome or Safari. A high-speed Internet connection is recommended.


Copyright 2021 American Academy of CME, Inc.